Local Application of Autologous Bone Marrow Cells for Treatment of Chronic Diabetic Ulcers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00292357
Recruitment Status : Unknown
Verified April 2007 by Heidelberg University.
Recruitment status was:  Recruiting
First Posted : February 15, 2006
Last Update Posted : January 18, 2010
Information provided by:
Heidelberg University

Brief Summary:
Bone marrow cells were previously shown to enhance wound healing in experimental diabetes. In this pilot study, patients with chronic diabetic ulcers not healing under conventional therapy, will be treated with local application of autologous bone marrow cells.

Condition or disease Intervention/treatment Phase
Diabetic Foot Diabetes Complications Procedure: Application of autologous bone marrow Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Primary Outcome Measures :
  1. Safety and Feasibility
  2. Healing velocity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diabetes mellitus
  • chronic non-healing foot ulcers (>4weeks)

Exclusion Criteria:

  • Charcot foot
  • Non-diabetic ulcers
  • Ulcers healing under conventional therapy
  • Sepsis
  • Hematologic disorders
  • Pregnancy
  • Acute inflammatory disorders
  • Chemotherapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00292357

Contact: Per Humpert, MD +49 6221 56 ext 8787

Medizinische Klinik 1, Universitätsklinikum Heidelberg Recruiting
Heidelberg, Germany, 69120
Contact: Per M Humpert, MD    +49 6221 56 ext 8787   
Sponsors and Collaborators
Heidelberg University
Principal Investigator: Peter Nawroth, MD University of Heidelberg, Dept. Medicine 1, Germany Identifier: NCT00292357     History of Changes
Other Study ID Numbers: HD-Med1-01/06
First Posted: February 15, 2006    Key Record Dates
Last Update Posted: January 18, 2010
Last Verified: April 2007

Additional relevant MeSH terms:
Diabetic Foot
Diabetes Complications
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Foot Ulcer
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies